



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Regulation Revision Committee has been ordered and called for 8:30 a.m. on Wednesday, January 16, 2019 at the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 01-14-2019**

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Consideration of Minutes from Previous Meeting – November 7, 2018
6. Old Business
  - a. Secure & Responsible Drug Disposal Act of 2010 & DEA Rules for Controlled Substances [04-01-2015]  
*Regulatory Proposal 2018-B ~ Drug Disposal by Pharmacies (Draft #3)*
  - b. Compounding in nuclear pharmacies [04-01-2015]
  - c. Review of centralized prescription dispensing (LAC 46:LIII.1141) [08-23-2017]
  - d. Electronic transmission of chart orders to pharmacies serving long-term care patients; now includes Act 2018-602, to revise Chaps. 11 and 25 [11-15-2017]  
*Regulatory Proposal 2019-A ~ Chart Orders (Draft #1)*
  - e. Review of NABP Model Rules for Automated Medication Systems and Telepharmacy [03-23-2018]
  - f. Automatic enrollment of pharmacists access to PMP data [08-15-2018]
  - g. Review of PMP Law and request for FraudRx® Alert access to PMP database [08-15-2018]
  - h. Compounding copies of commercially available drug products [10-19-2018]  
*Regulatory Proposal 2018-N ~ Compounding Copies (Draft #1)*  
*Regulatory Proposal 2018-N ~ Pharmacy Compounding (Draft #2)*

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purpose of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

6. Old Business (cont.)
  - i. Review of Proposed Memorandum of Understanding Between FDA and States re Distribution of Compounded Drug Products [10-19-2018]
7. New Business
  - a. Reinstatement of pharmacist license on voluntary inactive status [11-13-2018]
  - b. Rule for automated medication systems to allow correctional centers [11-14-2018]
  - c. Amount of THC in dosage forms and packaging [11-14-2018]  
*Regulatory Proposal 2019-B ~ Marijuana Permit Revisions (Draft #1)*
  - d. Patient identification cards in medical marijuana program [11-14-2018]
  - e. Annual update to state list of controlled substances [11-15-2018]  
*Legislative Proposal 2019-A ~ CDS Update (Draft #1)*  
*Legislative Proposal 2019-A ~ CDS Update (Draft #2)*
  - f. Legislative authority for CBC for certain CDS applicants [11-27-2018]  
*Legislative Proposal 2019-B ~ CBC for CDS (Draft #1)*
  - g. PMP access for federal jurisdictions, EHR, and Rx systems [12-12-2018]  
*Legislative Proposal 2019-C ~ Access to PMP (Draft #1)*
8. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purpose of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.